COMBINATION THERAPY OF A TYPE II ANTI - CD20 ANTIBODY WITH A PROTEASOME INHIBITOR

摘要

The present invention is directed to the use an type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with a proteasome inhibitor.